Agios Pharmaceuticals (AGIO)
$37.49 0.25 (0.67%)
17:59 EDT AGIO Stock Quote Delayed 20 Minutes
Previous Close $37.49
Market Cap 2.16B
PE Ratio -5.50
Volume (Avg. Vol.) 714,900
Day's Range 36.00 - 38.44
52-Week Range 27.77 - 68.85
Dividend & Yield N/A (N/A)
AGIO Stock Predictions, Articles, and Agios Pharmaceuticals News
- From InvestorPlace
- From the Web
Big biotech buyouts have already started happening. These five biotech stocks could be the next to go.
Celgene buying out Agios would make sense but either way the company's work on cellular metabolism and gene deleting is interesting the bulls the most. Agios stock is a good buy on its own merits.
These seven rare stocks have received only "buy" ratings from Wall Street's best analysts, with more upside predicted to come.
Recent 13-D and 13-G filings are windows into activist investors activity. We look at Liberty Sirius XM Group and 11 others
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Why Agios Pharmaceuticals Inc (AGIO), LPL Financial Holdings Inc (LPLA) and Humana Inc (HUM) Are 3 of Today’s Worst Stocks
Agios (AGIO), LPL Financial (LPLA) and Humana (HUM) were wishing the weekend could have lasted one more day on Monday.
These 10 stocks to buy are the perfect way to load up before the seasonally strong October-through-December period.
This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Here's why Agios Pharmaceuticals Inc (AGIO), Zulily Inc (ZU) and Aruba Networks, Inc. (ARUN) are three of today's worst stocks.
This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
The grades of eight biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
From Market News Video
Investors in Agios Pharmaceuticals Inc (AGIO) saw new options begin trading this week, for the November 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
From Simply Wall St
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/heres-why-were-watching-agios-pharmaceuticalss-nasdaqagio-cash-burn-situation/">Read More...</a></div>
From Market News Video
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Banc Of California Inc (BANC), where a total volume of 8,233 contracts has been traded thus far today, a contract volume which is representative of approximately 823,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 164.2% of BANC's average daily trading volume over the past month, of 501,320 shares..
Navellier RatingsPowered by Portfolio Grader